Report of Foreign Issuer (6-k)
September 20 2016 - 7:24AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of September 2016
001-36203
(Commission
File Number)
CAN-FITE
BIOPHARMA LTD.
(Exact
name of Registrant as specified in its charter)
10
Bareket Street
KiryatMatalon,
P.O. Box 7537
Petach-Tikva
4951778, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form 20-F
or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(7): ____
This
Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant's Registration Statements
on Form F-3 (File Nos. 333-195124, 333-199033, 333-204795 and 333-209037), to be a part thereof from the date on which this report
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On
September 20, 2016, Can-Fite BioPharma Ltd. (the “Company”) issued a press release announcing that a peer reviewed
scientific journal published an article reporting on the results of preclinical studies conducted by the Company with respect
to the Company’s liver cancer drug candidate CF102. A copy of this press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Exhibit
Index
Exhibit
No.
|
|
Description
|
99.1
|
|
Press
Release, dated September 20, 2016
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Can-FiteBioPharma
Ltd.
|
|
|
|
Date:
September 20, 2016
|
By:
|
/s/
Pnina Fishman
|
|
|
Pnina
Fishman
|
|
|
Chief
Executive Officer
|
4
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024